|
US5759833A
(en)
|
1994-05-27 |
1998-06-02 |
Cubist Pharmaceuticals, Inc. |
Human isoleucyl-tRNA synthetase proteins, nucleic acids and tester strains comprising same
|
|
JP2002508959A
(ja)
|
1998-01-14 |
2002-03-26 |
ヒューマン ジーン セラピー リサーチ インスティテュート |
ヒトのサプレッサーｔＲＮＡオリゴヌクレオチド、及びそれを用いる方法
|
|
US6844148B1
(en)
*
|
1998-09-24 |
2005-01-18 |
Pharmacia & Upjohn Company |
Alzheimer's disease secretase, APP substrates therefor, and uses therefor
|
|
ATE318923T1
(de)
|
2000-06-01 |
2006-03-15 |
Univ North Carolina |
Doppelsträngige parvovirus-vektoren
|
|
JP5642916B2
(ja)
|
2003-04-17 |
2014-12-17 |
ザ スクリプス リサーチ インスティテュート |
真核遺伝コードの拡張
|
|
EP2410331B1
(en)
|
2003-06-18 |
2015-09-23 |
The Scripps Research Institute |
Aminoacyl-tRNA synthetase for aminoacylation tRNA with unnatural amino acids
|
|
WO2005094370A2
(en)
|
2004-03-29 |
2005-10-13 |
The General Hospital Corporation |
Oligonucleotide complex compositions and methods of use as gene alteration tools
|
|
JP5697297B2
(ja)
|
2004-05-14 |
2015-04-08 |
ロゼッタ ジノミクス リミテッド |
マイクロｎａｓおよびその使用
|
|
SI2049664T1
(sl)
|
2006-08-11 |
2012-04-30 |
Prosensa Technologies Bv |
Enojna veriga oligonukleotidov, komplementarna repetitivnim elementom, za zdravljenje genetskih bolezni, povezanih z nestabilnostjo dnk ponovitev
|
|
EP2489732A1
(en)
|
2007-05-31 |
2012-08-22 |
Novozymes Inc. |
Compositions for degrading cellulosic material
|
|
WO2012161144A1
(ja)
|
2011-05-20 |
2012-11-29 |
学校法人 福岡大学 |
Rna配列上の修飾を識別するリボザイムおよびそれを用いたrna開裂方法
|
|
EP3730618A1
(en)
|
2011-11-18 |
2020-10-28 |
Alnylam Pharmaceuticals, Inc. |
Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
|
|
LT2841578T
(lt)
|
2012-04-23 |
2017-09-25 |
Biomarin Technologies B.V. |
Rnr moduliuojantys oligonukleotidai su pagerintomis savybėmis, skirti neuromuskulinių susirgimų gydymui
|
|
RS54944B1
(sr)
|
2012-07-12 |
2016-11-30 |
Proqr Therapeutics Ii Bv |
Oligonukleotidi za pravljenje promena u sekvencama ciljanih rnk molekula prisutnih u živoj ćeliji
|
|
US9650627B1
(en)
|
2012-07-19 |
2017-05-16 |
University Of Puerto Rico |
Site-directed RNA editing
|
|
CN113355357B
(zh)
|
2012-12-12 |
2024-12-03 |
布罗德研究所有限公司 |
对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
|
|
MX374532B
(es)
|
2013-06-17 |
2025-03-06 |
Broad Inst Inc |
Suministro, uso y aplicaciones terapéuticas de los sistemas y composiciones crispr-cas, para actuar sobre trastornos y enfermedades utilizando componentes víricos.
|
|
HRP20200250T1
(hr)
|
2013-08-08 |
2020-05-29 |
The Scripps Research Institute |
Metoda site-specifično enzimsko obilježavanje nukleinskih kiselina in vitro ugradnjom neprirodnih nukleotida
|
|
EP3041958B1
(en)
|
2013-09-04 |
2019-12-04 |
Cold Spring Harbor Laboratory |
Reducing nonsense-mediated mrna decay
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
WO2015120197A1
(en)
|
2014-02-05 |
2015-08-13 |
Regents Of The University Of California |
Rna editing biomarkers for diagnosis, pharmacological screening and prognostication in cancer
|
|
TWI638047B
(zh)
|
2014-04-09 |
2018-10-11 |
史基普研究協會 |
藉由核酸三磷酸酯轉運子將非天然或經修飾的核苷三磷酸酯輸入至細胞中
|
|
EP3140403A4
(en)
*
|
2014-05-09 |
2017-12-20 |
Université Laval |
Prevention and treatment of alzheimer's disease by genome editing using the crispr/cas system
|
|
CA2957661A1
(en)
|
2014-08-09 |
2016-02-18 |
Kevin FLANIGAN |
Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd gene
|
|
US12359197B2
(en)
*
|
2014-12-12 |
2025-07-15 |
Etagen Pharma, Inc. |
Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
|
|
EP3234134B1
(en)
*
|
2014-12-17 |
2020-05-27 |
ProQR Therapeutics II B.V. |
Targeted rna editing
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
GB201503408D0
(en)
|
2015-02-27 |
2015-04-15 |
Proqr Therapeutics N V |
Oligonucleotides
|
|
GB201504124D0
(en)
|
2015-03-11 |
2015-04-22 |
Proqr Therapeutics B V |
Oligonucleotides
|
|
EP3288594B1
(en)
|
2015-04-27 |
2022-06-29 |
The Trustees of The University of Pennsylvania |
Dual aav vector system for crispr/cas9 mediated correction of human disease
|
|
EP3323890A4
(en)
|
2015-07-14 |
2019-01-30 |
Fukuoka University |
METHOD OF INDUSTRYING SITE-SPECIFIC RNA MUTATIONS, TARGETED EDITING GUIDE RNA USED IN THE METHOD AND TARGET RNA TARGET EDITING GUIDE RNA COMPLEX
|
|
JP7044373B2
(ja)
|
2015-07-15 |
2022-03-30 |
ラトガース，ザ ステート ユニバーシティ オブ ニュージャージー |
ヌクレアーゼ非依存的な標的化遺伝子編集プラットフォームおよびその用途
|
|
IL320434A
(en)
|
2015-07-22 |
2025-06-01 |
Wave Life Sciences Ltd |
Oligonucleotide preparations and methods
|
|
WO2017040477A1
(en)
|
2015-08-31 |
2017-03-09 |
The University Of Chicago |
Composition and methods for detecting adenosine modifications
|
|
DE102015012522B3
(de)
|
2015-09-26 |
2016-06-02 |
Eberhard Karls Universität Tübingen |
Verfahren und Substanzen zur gerichteten RNA-Editierung
|
|
EP3359667A1
(en)
|
2015-10-05 |
2018-08-15 |
ProQR Therapeutics II B.V. |
Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion
|
|
IL295755A
(en)
|
2015-10-09 |
2022-10-01 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
|
AU2016337034A1
(en)
|
2015-10-16 |
2018-05-10 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for use in treating Alzheimer's disease
|
|
US10370667B2
(en)
|
2015-11-18 |
2019-08-06 |
Rosalind Franklin University Of Medicine And Science |
Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease
|
|
WO2017106767A1
(en)
|
2015-12-18 |
2017-06-22 |
The Scripps Research Institute |
Production of unnatural nucleotides using a crispr/cas9 system
|
|
CU24649B1
(es)
*
|
2016-03-19 |
2023-02-13 |
Exuma Biotech Corp |
Retrovirus recombinantes incompetentes de replicación para la transducción de linfocitos y expansión regulada de los mismos
|
|
PL3458074T3
(pl)
|
2016-05-16 |
2024-11-12 |
Board Of Regents Of The University Of Texas System |
KOMPOZYCJA DO DOSTARCZANIA tRNA W POSTACI NANOCZĄSTEK I SPOSOBY ICH STOSOWANIA
|
|
CN109642231A
(zh)
|
2016-06-17 |
2019-04-16 |
博德研究所 |
Vi型crispr直向同源物和系统
|
|
WO2017220751A1
(en)
|
2016-06-22 |
2017-12-28 |
Proqr Therapeutics Ii B.V. |
Single-stranded rna-editing oligonucleotides
|
|
WO2018017144A1
(en)
|
2016-07-19 |
2018-01-25 |
Brandeis University |
Compositions and methods for identifying rna binding polypeptide targets
|
|
CN110214183A
(zh)
|
2016-08-03 |
2019-09-06 |
哈佛大学的校长及成员们 |
腺苷核碱基编辑器及其用途
|
|
CN110352244B
(zh)
|
2016-09-01 |
2023-03-21 |
ProQR治疗上市公司Ⅱ |
化学修饰的编辑rna的单链寡核苷酸
|
|
WO2018045336A1
(en)
|
2016-09-02 |
2018-03-08 |
PFFA Acquisition LLC |
Database and system architecture for analyzing multiparty interactions
|
|
GB201616202D0
(en)
|
2016-09-23 |
2016-11-09 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of eye deisease
|
|
EP3565608A4
(en)
|
2017-01-05 |
2020-12-16 |
Rutgers, The State University of New Jersey |
TARGETED GENE EDITING PLATFORM INDEPENDENT OF BICATENARY DNA BREAKAGE AND ITS USES
|
|
EP3571300A1
(en)
|
2017-01-19 |
2019-11-27 |
ProQR Therapeutics II B.V. |
Oligonucleotide complexes for use in rna editing
|
|
CN110612353A
(zh)
|
2017-03-03 |
2019-12-24 |
加利福尼亚大学董事会 |
经由抑制性tRNAs和脱氨酶对突变进行RNA靶向
|
|
GB201706009D0
(en)
|
2017-04-13 |
2017-05-31 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of stargardt disease
|
|
WO2018208998A1
(en)
|
2017-05-10 |
2018-11-15 |
The Regents Of The University Of California |
Directed editing of cellular rna via nuclear delivery of crispr/cas9
|
|
US11866697B2
(en)
|
2017-05-18 |
2024-01-09 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
WO2018237372A1
(en)
|
2017-06-23 |
2018-12-27 |
Cornell University |
RNA MOLECULES, METHODS FOR PRODUCING CIRCULAR RNA, AND METHODS OF TREATMENT
|
|
KR102761791B1
(ko)
|
2017-06-26 |
2025-02-05 |
더 브로드 인스티튜트, 인코퍼레이티드 |
표적화된 핵산 편집을 위한 crispr/cas-아데닌 데아미나아제 기반 조성물, 시스템 및 방법
|
|
WO2019014262A1
(en)
|
2017-07-11 |
2019-01-17 |
The Scripps Research Institute |
INCORPORATION OF NON-NATURAL NUCLEOTIDES AND METHODS OF IN VIVO USE THEREOF
|
|
JP7325341B2
(ja)
|
2017-07-11 |
2023-08-14 |
シンソークス，インク． |
非天然ヌクレオチドの組み込み及びその方法
|
|
CN111801345A
(zh)
|
2017-07-28 |
2020-10-20 |
哈佛大学的校长及成员们 |
使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
|
|
US10476825B2
(en)
|
2017-08-22 |
2019-11-12 |
Salk Institue for Biological Studies |
RNA targeting methods and compositions
|
|
GB201714027D0
(en)
|
2017-09-01 |
2017-10-18 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of huntington's disease
|
|
WO2019071048A1
(en)
*
|
2017-10-04 |
2019-04-11 |
The Broad Institute, Inc. |
SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITION
|
|
WO2019071274A1
(en)
|
2017-10-06 |
2019-04-11 |
Oregon Health & Science University |
Compositions and methods for editing rna
|
|
WO2019084062A1
(en)
|
2017-10-23 |
2019-05-02 |
The Broad Institute, Inc. |
SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITION
|
|
JP7385282B2
(ja)
|
2017-11-07 |
2023-11-22 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
環状ｒｎａ分子のための方法及び組成物
|
|
WO2019104094A2
(en)
|
2017-11-21 |
2019-05-31 |
The Regents Of The University Of California |
Fusion proteins and methods for site-directed genome editing
|
|
JP7333508B2
(ja)
|
2017-12-06 |
2023-08-25 |
学校法人福岡大学 |
オリゴヌクレオチド、その製造方法及び標的ｒｎａの部位特異的編集方法
|
|
WO2019158475A1
(en)
*
|
2018-02-14 |
2019-08-22 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for rna editing
|
|
GB201803010D0
(en)
|
2018-02-26 |
2018-04-11 |
Royal Holloway & Bedford New College |
Neurodegenerative disorders
|
|
KR20250133482A
(ko)
|
2018-05-11 |
2025-09-05 |
빔 테라퓨틱스, 인크. |
프로그래밍가능한 염기 편집기 시스템을 이용하여 단일 뉴클레오티드 다형성을 편집하는 방법
|
|
GB201808146D0
(en)
|
2018-05-18 |
2018-07-11 |
Proqr Therapeutics Ii Bv |
Stereospecific Linkages in RNA Editing Oligonucleotides
|
|
JP7347830B2
(ja)
|
2018-06-29 |
2023-09-20 |
エバーハルト カール ウニヴェルジテート テュービンゲン |
Ｒｎａ編集のための人工核酸
|
|
WO2020018918A1
(en)
|
2018-07-19 |
2020-01-23 |
The Board Of Trustees Of The University Of Illinois |
Methods for exon skipping and gene knockout using base editors
|
|
WO2020023655A1
(en)
|
2018-07-24 |
2020-01-30 |
Flagship Pioneering, Inc. |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
US20220010333A1
(en)
|
2018-09-06 |
2022-01-13 |
The Regents Of The University Of California |
Rna and dna base editing via engineered adar recruitment
|
|
EP3864152B1
(en)
|
2018-10-12 |
2023-08-16 |
Peking University |
Methods and compositions for editing rnas
|
|
JP2022513159A
(ja)
|
2018-11-29 |
2022-02-07 |
フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド |
Ｒｎａを調節する方法
|
|
JP2022513719A
(ja)
|
2018-12-06 |
2022-02-09 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド組成物及びその方法
|
|
BR102019009665A2
(pt)
|
2018-12-21 |
2022-02-08 |
Jacques P. Tremblay |
Modificação da proteína precursora beta amiloide (app) através da edição de base usando o sistema crispr/cas9
|
|
EP3906308A1
(en)
|
2018-12-31 |
2021-11-10 |
Research Institute at Nationwide Children's Hospital |
Dux4 rna silencing using rna targeting crispr-cas13b
|
|
EP3914260A4
(en)
|
2019-01-22 |
2023-05-17 |
Korro Bio, Inc. |
RNA-EDITING OLIGONUCLEOTIDES AND THEIR USE
|
|
US20200385713A1
(en)
|
2019-01-22 |
2020-12-10 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
CA3127243A1
(en)
|
2019-01-22 |
2020-07-30 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
JP2022518808A
(ja)
|
2019-01-28 |
2022-03-16 |
プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ |
レーバー先天黒内障の処置のためのアンチセンスオリゴヌクレオチド
|
|
US12398393B2
(en)
|
2019-01-28 |
2025-08-26 |
Proqr Therapeutics Ii B.V. |
RNA-editing oligonucleotides for the treatment of usher syndrome
|
|
CN113423385A
(zh)
|
2019-02-01 |
2021-09-21 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
|
GB201901873D0
(en)
|
2019-02-11 |
2019-04-03 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for nucleic acid editing
|
|
US20220177894A1
(en)
|
2019-04-02 |
2022-06-09 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for immunotherapy
|
|
GB201904709D0
(en)
|
2019-04-03 |
2019-05-15 |
Proqr Therapeutics Ii Bv |
Chemically modified oligonucleotides
|
|
EP3956449B1
(en)
|
2019-04-15 |
2026-02-25 |
EdiGene Therapeutics (Beijing) Inc. |
Methods and compositions for editing rnas
|
|
CA3136172A1
(en)
|
2019-04-18 |
2020-10-22 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of usher syndrome
|
|
GB201905732D0
(en)
|
2019-04-24 |
2019-06-05 |
Proqr Therapeutics Ii Bv |
RNA editing inhibitors and methods of use
|
|
EP3981436A4
(en)
|
2019-06-05 |
2024-06-19 |
Fukuoka University |
Stable target-editing guide rna having chemically modified nucleic acid introduced thereinto
|
|
AU2020290517B2
(en)
|
2019-06-13 |
2026-02-26 |
Proqr Therapeutics Ii B.V. |
Antisense RNA editing oligonucleotides comprising cytidine analogs
|
|
WO2020254249A1
(en)
|
2019-06-21 |
2020-12-24 |
Proqr Therapeutics Ii B.V. |
Delivery of nucleic acids for the treatment of auditory disorders
|
|
EP3997229A4
(en)
|
2019-07-12 |
2024-07-03 |
Peking University |
TARGETED RNA EDITING BY HARNESSING ENDOGENOUS ADAR USING MODIFIED RNA
|
|
WO2021018750A1
(en)
|
2019-07-26 |
2021-02-04 |
Proqr Therapeutics Ii B.V. |
Ophthalmic compositions comprising viscosifying polymers and nucleic acids
|
|
EP4008784A1
(en)
|
2019-08-01 |
2022-06-08 |
Astellas Pharma Inc. |
Guide rna for targeted-editing with functional base sequence added thereto
|
|
JP7738323B2
(ja)
|
2019-09-27 |
2025-09-12 |
学校法人福岡大学 |
オリゴヌクレオチド及び標的ｒｎａの部位特異的編集方法
|
|
AU2020395113A1
(en)
|
2019-12-02 |
2022-06-09 |
Shape Therapeutics Inc. |
Therapeutic editing
|
|
US20230059753A1
(en)
|
2019-12-09 |
2023-02-23 |
Astellas Pharma Inc. |
Antisense guide rna with added functional region for editing target rna
|
|
CA3158528A1
(en)
|
2019-12-23 |
2021-07-01 |
Jim SWILDENS |
Antisense oligonucleotides for nucleotide deamination in the treatment of stargardt disease
|
|
KR20220119129A
(ko)
|
2019-12-30 |
2022-08-26 |
에디진 테라퓨틱스 (베이징) 인크. |
Leaper 기술에 기반한 mps ih 치료 방법 및 조성물
|
|
BR112022012921A2
(pt)
|
2019-12-30 |
2022-09-06 |
Edigene Therapeutics Beijing Inc |
Métodos para editar de forma alvejada ácido ribonucleico e para tratar a síndrome de usher tipo ii, ácido ribonucleico de recrutamento da adenosina desaminase, construto ou vetor de entrega, célula, e, uso do ácido ribonucleico de recrutamento da adenosina desaminase ou do construto ou vetor de entrega
|
|
WO2021136520A1
(zh)
|
2019-12-31 |
2021-07-08 |
博雅辑因（北京）生物科技有限公司 |
一种靶向编辑rna的新方法
|
|
CA3166720A1
(en)
|
2020-03-04 |
2021-09-10 |
Jim SWILDENS |
Antisense oligonucleotides for use in the treatment of usher syndrome
|
|
AU2021257508A1
(en)
|
2020-04-15 |
2022-11-17 |
Edigene Therapeutics (Beijing) Inc. |
Method and drug for treating Hurler syndrome
|
|
CN115777020A
(zh)
|
2020-04-22 |
2023-03-10 |
塑造治疗公司 |
使用snrna组分的组合物和方法
|
|
JP2023528039A
(ja)
|
2020-05-26 |
2023-07-03 |
シェイプ セラピューティクス インコーポレイテッド |
改変環状ポリヌクレオチド
|
|
KR102606949B1
(ko)
|
2020-06-26 |
2023-11-29 |
애터미주식회사 |
스마트 칫솔 및 스마트 살균기를 포함하는 구강 관리 시스템
|
|
EP4256050A4
(en)
|
2020-12-01 |
2025-01-22 |
Shape Therapeutics Inc. |
High throughput rna-editing screening methods
|